Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chronomodulated capecitabine pharmacology study
NL-OMON40756Phase 1Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of capecitabine in cancer, sponsored by Netherlands Cancer Institute. Started Jun 2014; status: recruiting.
02
Drugs
capecitabine
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON40756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40756.